A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.

已完结 40 由 wangzzzz 发布于 2025/8/6 9:47:37

DOI:10.1182/blood.2024027681
作者：Sherilyn A Tuazon,?Andrew J Portuguese,?Margot J Pont,?Andrew J Cowan,?Gabriel O Cole,?Blythe D Sather,?Xiaoling Song,?Sushma Thomas,?Brent L Wood,?Michelle Blake,?Melissa G Works,?Mazyar Shadman,?Emi
文献类型：期刊论文
补充材料：仅需补充材料
文献链接：https://doi.org/10.1182/blood.2024027681

American Society of Hematology (ASH)

Abstract：Abstract: FCARH143, an autologous B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell (CAR-T) therapy, which incorporates a fully human BCMA-specific single chai

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Comparative genomics approach to infer ancestral cell karyotypes and reconstruct the evolutionary trajectories of plant chromosomes.